Singaporean analytics startup Biofourmis raises US$1M in angel funding led by SpesNet and Eden Strategy
Biofourmis has been actively working with the healthcare sector to offer predictive, precise and meaningful insights into one’s health
Biofourmis, Singapore-based personalised physiological data analytics firm, today announced that the company has secured US$1 million in angel funding, led by SpesNet and Eden Strategy. Biofourmis has been actively working with the healthcare sector to offer predictive, precise and meaningful insights into one’s health.
Biofourmis’ product Biovitals is an analytics engine that uses cognitive technology and advanced machine learning to provide actionable health insights.
Also Read: Tricog gets Series A to help doctors detect patients’ heart complications within minutes
Biovitals intelligently interprets any form of data formulating personalised health models that are understandable and actionable displaying real-time patient information and physiological changes, thus, offering real-time suggestions for proactive and preventative healthcare actions especially in cardiovascular diseases.
“With the increasing uptake of wearable technology and biosensors, there is an explosion of healthcare data being created daily. Our vision is to empower people by making personalised healthcare data understandable and actionable through cutting-edge technology,” said Kuldeep Singh, Founder and CEO, Biofourmis, in a press statement.
Founded in 2015, Biofourmis aims to transform the way health is understood and encourage preventive and proactive healthcare.
The post Singaporean analytics startup Biofourmis raises US$1M in angel funding led by SpesNet and Eden Strategy appeared first on e27.
